Decreased expression of ferroportin in prostate cancer

By Xue Dong   Zhou CuiXing   Shi YunBo   Lu Hao   He XiaoZhou  

Oncology Letters, Vol. 10, Iss. 2, 2015-08 ,pp. : 913-916

Spandidos Publications

Access to resources Recommend Favorite

Treatment for intermediate and high-risk prostate cancer: Controversial issues and the role of hyperthermia

By Maluta Sergio   Dall'oglio Stefano   Nadalini Luisa  

International Journal of Hyperthermia, Vol. 26, Iss. 8, 2010-12 ,pp. : 765-774

Informa Healthcare

Access to resources Recommend Favorite

Array CGH as a potential predictor of radiocurability in intermediate risk prostate cancer

By Ishkanian Adrian S.   Zafarana Gaetano   Thoms John   Bristow Robert G.  

Acta Oncologica, Vol. 49, Iss. 7, 2010-10 ,pp. : 888-894

Informa Healthcare

Access to resources Recommend Favorite

What defines intermediate-risk prostate cancer? Variability in published prognostic models

By Williams S.G.   Millar J.L.   Dally M.J.   Sia S.   Miles W.   Duchesne G.M.  

International Journal of Radiation Oncology*Biology*Physics, Vol. 58, Iss. 1, 2004-01 ,pp. : 11-18

Elsevier

Access to resources Recommend Favorite

Implications of intermediate filament protein phosphorylation

By Ku N-O.   Liao J.   Chou C-F.   Omary M.B.  

Cancer and Metastasis Reviews, Vol. 15, Iss. 4, 1996-12 ,pp. : 429-444

Springer Publishing Company

Access to resources Recommend Favorite